ASCO 2020 | SAR408701 vs docetaxel in metastatic non-squamous NSCLC

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the phase III CARMEN-LC03 trial (NCT04154956) comparing SAR408701, an antibody-drug conjugate (ADC), with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) failing chemotherapy and immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).